Tycho Peterson
Stock Analyst at JP Morgan
(5.00)
# 1
Out of 4,853 analysts
131
Total ratings
61.96%
Success rate
269.62%
Average return
Main Sectors:
Stocks Rated by Tycho Peterson
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
A Agilent Technologies | Maintains: Overweight | $160 → $155 | $113.94 | +36.04% | 8 | May 29, 2025 | |
WGS GeneDx Holdings | Upgrades: Buy | $80 | $69.17 | +15.66% | 1 | May 9, 2025 | |
QDEL QuidelOrtho | Upgrades: Buy | $44 | $29.89 | +47.21% | 6 | May 8, 2025 | |
MTD Mettler-Toledo International | Upgrades: Hold | $1,200 → $1,100 | $1,164.61 | -5.55% | 8 | May 5, 2025 | |
DHR Danaher | Maintains: Overweight | $280 → $260 | $192.15 | +35.31% | 3 | Apr 22, 2025 | |
LH Labcorp Holdings | Maintains: Buy | $275 → $290 | $252.15 | +15.01% | 2 | Feb 6, 2025 | |
NEO NeoGenomics | Initiates: Buy | $22 | $7.12 | +208.99% | 1 | Dec 10, 2024 | |
DGX Quest Diagnostics | Assumes: Buy | $185 | $173.65 | +6.54% | 1 | Dec 10, 2024 | |
HOLX Hologic | Initiates: Hold | $85 | $63.08 | +34.76% | 7 | Dec 10, 2024 | |
QGEN Qiagen | Assumes: Buy | $43 → $56 | $45.58 | +22.04% | 5 | Dec 10, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $355 → $415 | $346.33 | +19.83% | 7 | Oct 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $35 | $30.34 | +15.36% | 3 | Aug 5, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $115 → $125 | $90.50 | +38.12% | 1 | Jul 29, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $24 | $9.11 | +163.45% | 7 | Jul 22, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $4 | $1.00 | +300.00% | 3 | Jun 3, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $5 → $3 | $0.74 | +304.31% | 1 | Jun 3, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $142 | $165.51 | -14.20% | 3 | Jun 3, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $48.41 | -33.90% | 2 | Jun 3, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $115 | $82.22 | +39.87% | 1 | Jun 3, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underperform | $25 → $20 | $4.91 | +307.33% | 1 | Jun 3, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $600 → $650 | $398.36 | +63.17% | 12 | Jun 3, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $26 → $9 | $12.18 | -26.08% | 1 | Sep 21, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.52 | - | 2 | Aug 16, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $12 | $2.19 | +447.95% | 2 | Aug 11, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $85 → $60 | $5.17 | +1,060.54% | 2 | Mar 2, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $3.08 | +646.75% | 1 | Aug 17, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $375 → $390 | $141.20 | +176.20% | 5 | May 28, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $1.13 | +1,935.40% | 1 | May 11, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $18 | $2.81 | +540.57% | 1 | Aug 10, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $188 → $200 | $558.06 | -64.16% | 9 | Jun 18, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $24 | $18.69 | +28.45% | 3 | Jun 1, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $65 → $45 | $15.90 | +183.11% | 5 | Mar 17, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $70 | $126.68 | -44.74% | 2 | Nov 2, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $120 | $147.37 | -18.57% | 1 | Feb 15, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.53 | - | 7 | Dec 13, 2017 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $37.68 | - | 5 | Nov 3, 2017 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $55 | $16.50 | +233.43% | 1 | Jul 19, 2016 |
Agilent Technologies
May 29, 2025
Maintains: Overweight
Price Target: $160 → $155
Current: $113.94
Upside: +36.04%
GeneDx Holdings
May 9, 2025
Upgrades: Buy
Price Target: $80
Current: $69.17
Upside: +15.66%
QuidelOrtho
May 8, 2025
Upgrades: Buy
Price Target: $44
Current: $29.89
Upside: +47.21%
Mettler-Toledo International
May 5, 2025
Upgrades: Hold
Price Target: $1,200 → $1,100
Current: $1,164.61
Upside: -5.55%
Danaher
Apr 22, 2025
Maintains: Overweight
Price Target: $280 → $260
Current: $192.15
Upside: +35.31%
Labcorp Holdings
Feb 6, 2025
Maintains: Buy
Price Target: $275 → $290
Current: $252.15
Upside: +15.01%
NeoGenomics
Dec 10, 2024
Initiates: Buy
Price Target: $22
Current: $7.12
Upside: +208.99%
Quest Diagnostics
Dec 10, 2024
Assumes: Buy
Price Target: $185
Current: $173.65
Upside: +6.54%
Hologic
Dec 10, 2024
Initiates: Hold
Price Target: $85
Current: $63.08
Upside: +34.76%
Qiagen
Dec 10, 2024
Assumes: Buy
Price Target: $43 → $56
Current: $45.58
Upside: +22.04%
Oct 8, 2024
Upgrades: Buy
Price Target: $355 → $415
Current: $346.33
Upside: +19.83%
Aug 5, 2024
Maintains: Underweight
Price Target: $28 → $35
Current: $30.34
Upside: +15.36%
Jul 29, 2024
Maintains: Hold
Price Target: $115 → $125
Current: $90.50
Upside: +38.12%
Jul 22, 2024
Upgrades: Buy
Price Target: $24
Current: $9.11
Upside: +163.45%
Jun 3, 2024
Initiates: Buy
Price Target: $4
Current: $1.00
Upside: +300.00%
Jun 3, 2024
Assumes: Hold
Price Target: $5 → $3
Current: $0.74
Upside: +304.31%
Jun 3, 2024
Initiates: Buy
Price Target: $142
Current: $165.51
Upside: -14.20%
Jun 3, 2024
Initiates: Buy
Price Target: $32
Current: $48.41
Upside: -33.90%
Jun 3, 2024
Assumes: Hold
Price Target: $115
Current: $82.22
Upside: +39.87%
Jun 3, 2024
Assumes: Underperform
Price Target: $25 → $20
Current: $4.91
Upside: +307.33%
Jun 3, 2024
Assumes: Buy
Price Target: $600 → $650
Current: $398.36
Upside: +63.17%
Sep 21, 2022
Downgrades: Underweight
Price Target: $26 → $9
Current: $12.18
Upside: -26.08%
Aug 16, 2022
Downgrades: Neutral
Price Target: n/a
Current: $3.52
Upside: -
Aug 11, 2022
Downgrades: Neutral
Price Target: $20 → $12
Current: $2.19
Upside: +447.95%
Mar 2, 2022
Maintains: Overweight
Price Target: $85 → $60
Current: $5.17
Upside: +1,060.54%
Aug 17, 2021
Initiates: Overweight
Price Target: $23
Current: $3.08
Upside: +646.75%
May 28, 2021
Maintains: Overweight
Price Target: $375 → $390
Current: $141.20
Upside: +176.20%
May 11, 2021
Initiates: Overweight
Price Target: $23
Current: $1.13
Upside: +1,935.40%
Aug 10, 2020
Initiates: Neutral
Price Target: $18
Current: $2.81
Upside: +540.57%
Jun 18, 2020
Maintains: Overweight
Price Target: $188 → $200
Current: $558.06
Upside: -64.16%
Jun 1, 2020
Maintains: Overweight
Price Target: $22 → $24
Current: $18.69
Upside: +28.45%
Mar 17, 2020
Maintains: Neutral
Price Target: $65 → $45
Current: $15.90
Upside: +183.11%
Nov 2, 2018
Maintains: Overweight
Price Target: $60 → $70
Current: $126.68
Upside: -44.74%
Feb 15, 2018
Maintains: Overweight
Price Target: $115 → $120
Current: $147.37
Upside: -18.57%
Dec 13, 2017
Downgrades: Underweight
Price Target: n/a
Current: $1.53
Upside: -
Nov 3, 2017
Downgrades: Neutral
Price Target: n/a
Current: $37.68
Upside: -
Jul 19, 2016
Initiates: Neutral
Price Target: $55
Current: $16.50
Upside: +233.43%